As was the case in dapagliflozin monotherapy, a drug manufacturer also presented no suitable data for the therapeutic indication in its dossier on the fixed combination with metformin. Dapagliflozin is approved both alone and in combination with other blood-glucose lowering drugs, including insulin. The fixed combination with metformin is an option for patients who are already taking dapagliflozin and metformin as separate tablets or for patients or who do not benefit sufficiently from the commonly used drug metformin. It can also be used together with other blood-glucose lowering drugs, including insulin, if metformin and these drugs are insufficient.

Source: Added benefit of the fixed combination of dapagliflozin, metformin is not proven, study finds